MedPath

Longeveron to Explore Partnerships for Alzheimer's Cell Therapy at Cell & Gene Meeting

• Longeveron will attend the Cell & Gene Meeting on the Mesa to seek partnerships for its Alzheimer's cell therapy program. • The company's Lomecel-B™ showed promising Phase 2a results, slowing disease worsening in mild Alzheimer's patients. • Lomecel-B™ has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA. • Longeveron also highlights its contract development and manufacturing capabilities at its cGMP facility.

Longeveron Inc. (NASDAQ: LGVN) will participate in the Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa, October 7-9, 2024, in Phoenix, Arizona. The company aims to explore potential partnerships and strategic opportunities for its cellular therapy program in Alzheimer's disease (AD). Longeveron will also highlight its contract development and manufacturing business.

Alzheimer's Disease Program

Longeveron's lead investigational therapeutic candidate, Lomecel-B™, is a proprietary, scalable, allogeneic cellular therapy. The CLEAR MIND Phase 2a clinical trial in mild Alzheimer's disease showed that Lomecel-B™ treated patients experienced an overall slowing or prevention of disease worsening compared to placebo. The trial met its primary safety and secondary efficacy endpoints, demonstrating statistically significant improvements in pre-specified clinical and biomarker endpoints in specific Lomecel-B™ groups compared to placebo.
Full results from the CLEAR MIND study were presented at the 2024 Alzheimer's Association International Conference (AAIC). Top-line results were announced on October 5, 2023, with additional clinical data and imaging biomarker results reported on December 20, 2023.
The U.S. FDA has granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease.

Contract Development and Manufacturing

Longeveron provides contract development and manufacturing services to pharmaceutical company clients at its 15,000 square feet current Good Manufacturing Practice (cGMP) facility in Miami, Florida. This facility contains 3,000 square feet of cleanroom space, including eight ISO 7 cleanrooms and ancillary areas, as well as 1,150 square feet of process development, quality control and warehousing space.
Longeveron has assembled a team of experts and proprietary technologies that enable it to take a systematic approach to rapidly develop improved cell therapies. Longeveron’s manufacturing expertise, capabilities and facility provide other pharmaceutical organizations the ability to advance their development programs without building their own manufacturing facility.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Genenta Science Enhances Cell Therapy Manufacturing with AGC Biologics

Genenta Science strengthens its partnership with AGC Biologics to enhance cell therapy manufacturing capabilities.
An exclusive GMP suite in Milan will be dedicated to producing Genenta's cell therapy product, ensuring cGMP compliance.

Lineage Cell Therapeutics Updates Shareholders on Progress and 2025 Outlook

Lineage Cell Therapeutics, a clinical-stage biotechnology company, has shared a letter with its stockholders detailing recent achievements, including advancements in its allogeneic cell therapy programs, and outlining its outlook for 2025. The company emphasizes its unique approach to cell transplantation, its financial strategy, manufacturing capabilities, and long-term goals, particularly focusing on its OpRegen® program for dry-AMD and other neurological cell transplant candidates.

Alzheimer's Disease: Cell and Gene Therapy Advances in 2024

Lexeo Therapeutics' LX1001 gene therapy shows dose-dependent APOE2 expression increase and reduced tau biomarkers in APOE4 homozygote Alzheimer's patients.
Lomecel-B cell therapy demonstrates safety and potential cognitive benefits in mild Alzheimer's patients, according to Phase 2a CLEAR MIND trial data.

Longeveron's Lomecel-B Shows Promise in HLHS and Alzheimer's Disease Trials

Longeveron's ELPIS II trial for HLHS, evaluating Lomecel-B™, has surpassed 80% enrollment and is deemed pivotal by the FDA for BLA submission.
Positive Phase 2a data from the CLEAR MIND trial, assessing Lomecel-B™ in mild Alzheimer's, was highlighted at the Alzheimer's Association International Conference.

Longeveron's Lomecel-B Shows Promise in Mild Alzheimer's Disease by Targeting MMP14

Longeveron presented data at CTAD24 showing Lomecel-B's potential in treating mild Alzheimer's by inhibiting MMP14, offering mechanistic and clinical insights.
The study found that Lomecel-B's ability to inhibit MMP14 correlates with improved clinical and biomarker outcomes in patients with mild Alzheimer's disease.

Faron Pharmaceuticals' Bexmarilimab Shows Promise in Myelodysplastic Syndrome Treatment

Faron Pharmaceuticals' BEXMAB trial shows a 79% overall response rate in relapsed/refractory myelodysplastic syndrome (r/r MDS) patients treated with bexmarilimab and azacitidine.
The median overall survival (mOS) in r/r MDS patients remains at 13.4 months, significantly longer than the 5-6 months typically expected with standard care.

Longeveron's Lomecel-B Data in Alzheimer's Disease to be Presented at CTAD24

Longeveron's Lomecel-B data, focusing on MMP14 inhibition, will be presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24).
The presentation will highlight Lomecel-B's bioactivity in treating mild Alzheimer's disease, offering mechanistic and clinical insights.

Ocugen Highlights Modifier Gene Therapy Platform at Cell & Gene Meeting on the Mesa

Ocugen's CEO, Dr. Shankar Musunuri, presented the company's modifier gene therapy platform at the 2024 Cell & Gene Meeting on the Mesa.
The presentation included updates on OCU400 for retinitis pigmentosa (Phase 3), OCU410 for geographic atrophy (Phase 2), and OCU410ST for Stargardt disease (Phase 1/2).

Longeveron Achieves FDA Alignment on Lomecel-B Pathway for Hypoplastic Left Heart Syndrome

Longeveron secured FDA agreement on key endpoints for its Phase 2b ELPIS II trial of Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS).
The FDA indicated that a successful ELPIS II trial, meeting specific conditions, could support a Biological License Application (BLA) submission for Lomecel-B™.

Cell and Gene Therapies Show Promise in Alzheimer's Disease Treatment

Longeveron's Lomecel-B, an allogeneic medicinal signaling cell therapy, has shown promise in Phase IIa trials by slowing disease progression in Alzheimer's patients.
Lexeo Therapeutics is developing gene therapies targeting APOE alleles, with LX1001 in Phase I/II trials, focusing on the 40-50% of Alzheimer's patients with APOE4.

Reference News

[1]
Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa
stocktitan.net · Sep 26, 2024

Longeveron Inc. (NASDAQ: LGVN) will participate in the Alliance for Regenerative Medicine's Cell & Gene Meeting on the M...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy